Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer

Ivan S. Donev¹, Wei Wang¹, Tadaaki Yamada¹, Qi Li¹, Shinji Takeuchi¹, Kunio Matsumoto², Takao Yamori³, Yasuhiko Nishioka⁴, Saburo Sone⁴, Seiji Yano¹,⁵

¹Division of Medical Oncology, and ²Division of Tumor Dynamics and Regulation, Cancer Research Institute, Kanazawa University, 13-1, Takara-machi, Kanazawa 920-0934, ³Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-10-6, Ariake, Koto-ku, Tokyo 135-8550, ⁴Department of Respiratory Medicine & Rheumatology, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Tokushima 770-8503, Japan.

⁵To whom correspondence should be addressed.

Division of Medical Oncology, Cancer Research Institute, Kanazawa University. Kanazawa, Ishikawa 920-0934

E-mail: syano@staff.kanazawa-u.ac.jp

Key words: HGF, gefitinib resistance, PI3K, Akt, lung cancer

Running Title: Transient PI3K inhibition overcomes HGF-mediated resistance
Grant support: This study was supported by Grants-in-Aid of Cancer Research from the Ministry of Education, Science, Sports, and Culture of Japan (S. Yano, 21390256 and 2212010A01).

Statement of Translational Relevance.

The acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is one of the most serious problems on the management of EGFR mutant lung cancer. We recently reported the novel mechanism that hepatocyte growth factor (HGF) induces EGFR-TKI resistance by activating MET which restores phosphorylation of downstream MAPK-ERK1/2 and PI3K-Akt pathways.

In the present study, we demonstrated that transient blockade of PI3K-Akt pathway by PI3K inhibitor and gefitinib could overcome HGF-mediated resistance to EGFR-TKIs by inducing apoptosis in both in vitro and in vivo models. Our findings indicate usefulness of double blockade of EGFR andPI3K, and further postulate the need to develop PI3K inhibitor analogues with more suitable pharamcokinetics and metabolic profiles, for more successful therapy of EGFR mutant lung cancer.
Abstract

Purpose: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, show favorable response to EGFR mutant lung cancer. However, the responders acquire resistance almost without exception. We recently reported that hepatocyte growth factor (HGF) induces EGFR-TKI resistance by activating MET which restores downstream MAPK-ERK1/2 and PI3K-Akt signaling. The purpose of this study was to determine whether inhibition of PI3K, a downstream molecule of both EGFR and MET, could overcome HGF-mediated EGFR-TKI resistance in EGFR mutant lung cancer cells, PC-9 and HCC827.

Experimental Design: We explored therapeutic effect of a class I PI3K inhibitor PI-103 on HGF-induced EGFR-TKI resistance in vitro and in vivo.

Results: Unlike gefitinib or erlotinib, continuous exposure with PI-103 inhibited proliferation of PC-9 and HCC827 cells, even in the presence of HGF. On the other hand, in gefitinib-resistant xenograft model using PC-9 cells mixed with HGF high producing fibroblasts, PI-103 monotherapy did not inhibit tumor growth. However, PI-103 combined with gefitinib successfully regressed gefitinib-resistant tumor. In vitro experiments considering short half life of PI-103 reveal that transient exposure of PI-103 combined with gefitinib caused sustained inhibition of Akt phosphorylation, but not ERK1/2 phosphorylation, resulting in induction of tumor cell apoptosis even in the presence of HGF.

Conclusions: These results indicate that transient blockade of PI3K-Akt pathway by PI-103 and gefitinib could overcome HGF-mediated resistance to EGFR-TKIs by inducing apoptosis in EGFR mutant lung cancer.
Introduction

Lung cancer is one of the most prevalent malignancies and the leading cause of cancer-related death worldwide. Non–small cell lung cancer (NSCLC) accounts for nearly 80% of lung cancer cases. Substantial efforts are being made to identify the optimal target for NSCLC therapy. The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib have been shown to inhibit epidermal growth factor receptor (EGFR) mediated downstream pathways including MAPK-ERK1/2 and PI3K-Akt, and to show favorable activity in NSCLC patients with mutant EGFR (1). Recent phase III clinical trials demonstrated that patients with EGFR mutant NSCLC had superior outcomes with gefitinib treatment, compared with standard first line cytotoxic chemotherapy (2-3). However, the patients develop acquired resistance to EGFR-TKIs almost without exceptions within a couple of years (4). In addition, 20-25% patients with EGFR activating mutations show intrinsic resistance to EGFR-TKIs.

Two genetically conferred mechanisms – T790M second mutation in EGFR (4-5), and the MET gene amplification (6) have been well reported to induce acquired resistance to EGFR-TKIs in EGFR mutant lung cancer. Recently, we indentified a third mechanism, hepatocyte growth factor (HGF)-induced resistance. HGF induces EGFR-TKI resistance by activating MET which restores phosphorylation of downstream MAPK-ERK1/2 and PI3K-Akt pathways (7-8). This is not a genetically conferred mechanism, and may be involved in both intrinsic resistance and acquired resistance to EGFR-TKIs in EGFR mutant lung cancer (7). While HGF is reported to be produced predominantly by stromal cells, it can act both autocrine and paracrine fashion when inducing resistance to EGFR-TKIs (7, 9). More recent studies demonstrated that HGF is frequently co-expressed, along with the T790M second mutation in EGFR (10) and MET gene amplification (8) in tumors of patients with acquired resistance to EGFR-TKIs, indicating importance of HGF as therapeutic target for overcoming resistance to EGFR-TKIs.
Several strategies are available to block HGF-MET mediated signaling, including ligand (HGF) blockade, MET tyrosine kinase inhibition, and inhibition of downstream molecules (PI3K/Akt, MAPK/ERK) (11). PI3Ks are responsible for the generation of 3-phosphorylated inositides, including the important second messenger PtIns(3,4,5)P3, resulting in activation of signal transduction pathways in many physiologic process (12). PI3Ks are divided into three classes based on their primary structures and in vitro substrate specificity (13), with class I PI3Ks being the most well characterized. Class I PI3Ks can be further subdivided into class IA (p110α, p110β, and p110δ) and class IB (p110γ) according to their structure and interaction with p85 and p55 regulatory subunits. Class IA PI3Ks, each composed of a p85 regulatory subunit and a p110 catalytic subunit, are the most widely involved in cancer (14). The major effector of PI3K in cancer is Akt, a serine-threonin kinase that is directly activated in response to PI3K (13-14). Recent studies indicate that the PI3K/Akt pathway plays crucial roles in resistance to various types of tyrosine kinase inhibitors, including EGFR TKIs (6, 15-17). Accordingly, a large numbers of PI3K inhibitors are being developed (18).

We sought to determine whether inhibition of PI3K signaling pathway could overcome EGFR-TKI resistance induced by HGF in EGFR mutant lung cancer. We found that transient exposure of class I PI3K inhibitor plus gefitinib was sufficient to overcome HGF-mediated resistance by inducing apoptosis of EGFR mutant lung cancer cells.
Materials and Methods

Cell cultures and reagents. The EGFR mutant human lung adenocarcinoma cell lines, with exon 19 deletion in EGFR PC-9 (del E746_A750) and HCC827 (del E746_A750), were purchased from Immuno-Biological Laboratories Co (Takasaki, Gunma, Japan) and American Type Culture Collection (Manassas, VA), respectively (19). The H1975 human lung adenocarcinoma cell line with EGFR-L858R/T790M double mutation (20) was kindly provided by Drs. John D. Minna (University of Texas Southwestern Medical Center) and Yoshitaka Sekido (Aichi Cancer Center Research Institute). Human lung embryonic fibroblasts, MRC-5, were obtained from RIKEN Cell Bank (Ibaraki, Japan). The PC-9, HCC827 and H1975 cell lines were maintained in RPMI 1640 medium supplemented with 10% FBS and antibiotics. The MRC-5 (P30-35) was cultured in 10% FBS DMEM. All cells were passaged for less than 3 months before renewal from frozen, early-passage stocks obtained from the indicated sources. Cells were regularly screened for mycoplasma with the use of a MycoAlert Mycoplasma Detection Kit (Lonza). Gefitinib, erlotinib, PI-103 and GDC-0941 were obtained from AstraZeneca (Cheshire, UK), Chugai Pharmaceutical Co (Tokyo), Calbiochem (Darmstadt, Germany), and Selleck Chemicals (Houston, TX), respectively. Human recombinant HGF was prepared as described previously (21).

Cell proliferation assay. Cell proliferation was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium (MTT) dye reduction method (22). Tumor cells (2 × 10^3/100 µL/well) were plated into each well of 96-well plates in RPMI 1640 with 10% FBS. After 24-h incubation, several concentrations of gefitinib, erlotinib, PI-103, and/or HGF were added to each well, and incubation was continued for a further 72 h or 48h. For short exposure to gefitinib and/or PI-103, tumor cells (8 × 10^3/800µL/well) were incubated in 24-well plates. After 24-h incubation several concentration of PI-103 and gefitinib were added for 1h, then washed two times with PBS and then replated with fresh medium. Viability was assessed at 48-h after initial exposure.
Cell proliferation was determined with MTT solution (2mg/ml; Sigma) as described previously (7). Each experiment was done at least three times, each with triplicate samples.

**Determination of Drug Synergy.** Cells were seeded at a density of 2x10^3 per well of a 96-well plate. Concentration ranges were chosen to span the complete dose-response range of both drugs. All treatments were performed in quadruplicate. Cell proliferation/viability was determined after 3 days by using MTT assay. Multiple drug effect analysis was performed by using CalcuSyn software (Biosoft, Cambridge, United Kingdom), which quantitatively describes the interaction between two or more drugs (23). This method assigns combination index (C.I.) values to each drug combination and defines drug synergy when a C.I. value is less than 1 or drug antagonism when a C.I. value is greater than 1.

**Coculture of lung cancer cells with fibroblasts.** Cells were cocultured in Transwell chambers separated by 8 μm pore filters. Tumor cells (8 ×10^3 cells/700 μL) with gefitinib and or PI-103 different doses were placed in the bottom chamber, and fibroblasts (10^4 cells/300 μL), were placed in the top chamber. After 72 h, the top chamber was removed, and cell proliferation was measured by MTT-assay. For short exposure to PI-103 and/or gefitinib the proliferation was assessed after 48h and drugs were administered for only 1h in different concentration, then each well were washed twice with PBS and new fresh media were added. Each experiment was done at least three times, each with triplicate samples.

**Assay for RNA interference.** Duplexed Stealth™ RNAi (Invitrogen) against Akt1-1 (5’-AUACCGGCAAAAGCGAUGGCUGCA-3’), Akt1-2 (5’-AACCUCUUCACAAUAGCCACGUC-3’), Akt1-3 (5’-UAGCGUGGCGCCAGUGCAUGU-3’) was used for RNA interference assay. One day before transfection, aliquots of 2×10^4 tumor cells in 400 μl of antibiotic-free medium were plated on 24-well plates. After incubation for 24 h, the cells were transfected with siRNA (50 pmol) or scramble RNA using Lipofectamine 2000 (1 μl) in accordance with the
manufacturer’s instructions. After 24-h incubation, the cells were washed with PBS, and incubated with or without gefitinib (0.1 μmol/L) and/or rhHGF (20 ng/ml) for an additional 72 h in antibiotic-containing medium. Cell proliferation was measured using a Cell Counting Kit-8 (Dojin, Tokyo, Japan) in accordance with the manufacturer’s instructions. Each experiment was performed at least in triplicate, and 3 times independently.

**Xenograft studies in SCID mice.** Suspensions of PC-9 cells (5 × 10⁶) with MRC-5 (5 × 10⁵) were injected subcutaneously into the backs of 5-week-old female SCID mice. Mice (n = 6 per group) were randomized to: a) control group, b) gefitinib only (25 mg/kg/d) orally, c) PI-103 only prepared in 20% 4-hydroxypropyl β-cyclodextrin (5 mg/kg/d) intraperitoneally, or d) gefitinib (25 mg/kg/d) and PI-103 (5 mg/kg/d). After 4 days (tumors diameter>4 mm), the treatment was started. The tumor volume was calculated (mm³ = width² × length/2). All animal experiments complied with the Guidelines for the Institute for Experimental Animals, Kanazawa University Advanced Science Research Center (approval no. AP-081088).

**Antibodies and Western blotting.** For Western blotting analysis, 40 μg of total protein were resolved by SDS polyacrylamide gel (Bio-Rad) electrophoresis and the proteins were then transferred onto polyvinylidene difluoride membranes (Bio-Rad). After washing four times, membranes were incubated with Blocking One (Nacalai Tesque, Inc.) for 1h at room temperature and then incubated overnight at 4ºC with the following primary antibodies: anti–Met (25H2), anti–phospho-Met (Y1234/Y1235) (3D7), anti–phospho EGFR(Y1068), anti–ErbB3 (1B2), anti–phospho-ErbB3 (Tyr1289) (21D3), anti–Akt, or phosphor–Akt (Ser473),anti–Cleaved Caspase-9 (Asp315),anti–Cleaved Caspase-3 (Asp175),anti–Cleaved PARP (Asp214) antibodies (1:1,000 dilution, Cell Signaling Technology), and anti–human EGFR (1 μg/mL), anti–human/mouse/rat extracellular signal–regulated kinase (ERK)-1/ERK2 (0.2 μg/mL), or anti–phospho ERK1/ERK2 (T202/Y204) (0.1 μg/mL) antibodies (R&D Systems). After washing thrice, membranes were incubated for 1 h at room temperature with species specific horseradish
peroxidase–conjugated secondary antibodies. Immunoreactive bands were visualized with SuperSignal West Dura Extended Duration Substrate Enhanced Chemiluminescent Substrate (Pierce Biotechnology). Each experiment was done at least thrice independently.

**TUNEL assay** Terminal deoxynucleotidyl transferase-mediated nick end labeling staining was performed using the Apoptosis Detection System (Promega, Madison, WI). Briefly, the frozen tissue sections (9-μm thick) were fixed with PBS containing 4% formalin. The slides were washed with PBS and permeabilized with 0.2% Triton-X-100. The samples were then equilibrated, and DNA strand breaks were labeled with fluorescein-12-dUTP by adding nucleotide mix and terminal deoxynucleotidyl transferase enzyme. The reaction was stopped with saline sodium citrate, and the localized green fluorescence of apoptotic cells was detected by fluorescence microscopy (x200).

**RT-PCR analysis.** Total RNA was isolated from MRC-5 cells treated with various concentration of PI-103 for 24h, with ISOGEN RNA extraction. Total RNAs were reversely transcribed using an Omniscript RT kit (Qiagen) according to the manufacturer's protocols. The primers for HGF and β-actin were as follow: HGF forward, 5’-CAGTGTTGAGAAGTTGAATGC-3’, reverse, 5’-GTGTCATTCCATAGTGAGAGTG-3’, β-actin forward, 5’-AAGAGAGGCATCCTCACCCT-3’, reverse, 5’-TACATGGCTGGGTTGCTG-3’. Polymerase chain reaction was done using Ex Taq Hot Start Version (Takara, Shiga, Japan). Cycles for HGF and β-actin were 28 and 26 respectively. The bands were visualized by ethidium bromide staining.

**Cell apoptosis assay.** Cell apoptosis induced by gefitinib was detected with an Annexin V-FITC Apoptosis Detection Kit I (BD Biosciences Phamingen) in accordance with the manufacturer's protocols as we described previously (7). The analysis was done on a FACSCalibur flow cytometer with CellQuest software (Becton Dickinson).
Statistical Analysis. Two-tailed Student’s t-test was performed when noted using GraphPad Software. Differences of P < 0.001 were considered statistically different (24).

Results

Continuous exposure of PI-103 effectively suppresses the in vitro proliferation of EGFR mutant lung cancer cells in the presence of HGF.

Both PC-9 and HCC827 cells were highly sensitive to continuous exposure (72h) to gefitinib and erlotinib. HGF alone did not affect proliferation of PC-9 cells, but it slightly stimulated the proliferation of HCC827 cells. Under these experimental conditions, HGF dose-dependently induced resistance to gefitinib and erlotinib of PC-9 and HCC827 cells (Fig. 1), as reported previously (7). Under the same experimental conditions, continuous exposure (72h) of PI-103 inhibited the proliferation of PC-9 and HCC827 cells, though the IC50 to PI-103 was higher (0.3µmol/L for HCC827; 0.8µmol/L for PC-9 cells) compared with gefitinib (0.01µmol/L for HCC827; 0.03µmol/L for PC-9 cells) and erlotinib (0.01µmol/L for HCC827; 0.02µmol/L for PC-9 cells). Importantly, HGF did not decrease sensitivity of PC-9 and HCC827 cells to PI-103, suggesting the potential of PI-103 to overcome HGF-induced resistance to gefitinib and erlotinib in vitro.

We recently reported that HGF induce resistance in lung cancer cells (H1975) with EGFR T790M second mutation to irreversible EGFR-TKI which is expected to overcome T790M second mutation mediated resistance to gefitinib or erlotinib (25). Interestingly, continuous exposure (72h) of PI-103 inhibited proliferation of H1975 cells in a dose dependent manner (Supplementary Fig. S1). HGF slightly stimulated proliferation of H1975 cells and induced resistance to irreversible EGFR-TKI, CL-387,785. However, HGF did not affect sensitivity of H1975 cells to PI-103. These results suggest that PI-103 have potential to overcome HGF-induced resistance to not only reversible EGFR-TKIs but also irreversible EGFR TKIs. Moreover,
combined use of PI-103 with CL-387,785 further inhibited proliferation of H1975 cells, irrespective of the presence of HGF.

We next examined whether PI-103 sensitized EGFR mutant lung cancer cells when combined with gefitinib in the presence or absence of HGF. PI-103 inhibited the proliferation of PC-9 and HCC827 cells in a dose-dependent manner. Gefitinib markedly suppressed the proliferation, and HGF induced resistance to gefitinib. Surprisingly, PI-103 combined with gefitinib further inhibited the proliferation of PC-9 and HCC827 cells not only in the absence of HGF, but also in the presence of HGF (Fig 2A). Proliferation data were analyzed by the established method of Chou and Talalay (23) using CalcuSyn software. The resulting combination index (C.I.) values were < 1 over most of the effect range of the drugs, demonstrating that the combination of PI-103 and gefitinib inhibited the proliferation synergistically in PC-9 and HCC827 cells. Same results were reproduced with GDC-0941 – a derivative of PI-103 with improved pharmacokinetic and pharmacodynamic properties that is active against all isoforms of class I PI3Ks and now used in clinical trials in patients with solid tumors (26) (Supplementary Fig. 2). This synergy was also observed in a co-culture system where HGF-high producing fibroblasts, MRC-5, induced gefitinib resistance. While PI-103 did not inhibit HGF expression in MRC-5 cells (Supplementary Fig. S3), PI-103 synergistically inhibited the proliferation of PC-9 and HCC827 cells, irrespective of the presence of MRC-5 cells, when combined with gefitinib (Fig 2B). These results suggest that PI3K inhibitor combined with gefitinib may be more beneficial than either monotherapy.

**PI-103 with or without gefitinib suppresses PI3K/Akt pathway even in the presence of HGF.**

To explore the molecular mechanism by which PI-103 combined with gefitinib showed greater anti-proliferative effect, we examined the phosphorylation of MET, EGFR, ErbB3, and their
downstream pathways (PI3K/Akt and ERK1/2) by Western blotting (Fig 3A). PC-9 and HCC827 cells expressed EGFR, ErbB3, and MET proteins, and these molecules were phosphorylated at various levels. These receptors and downstream molecules, such as Akt and ERK1/2, were also phosphorylated. While HGF alone did not affect phosphorylation of EGFR or ErbB3, it stimulated phosphorylation of MET and thereby activated Akt and ERK1/2. Although gefitinib inhibited phosphorylation of Akt and ERK1/2 in the absence of HGF, it failed to inhibited Akt and ERK1/2 phosphorylation in the presence of HGF. Importantly, PI-103 did not affect the phosphorylation of ERK1/2 or upstream molecules such as MET, EGFR, and ErbB3, but did inhibit the phosphorylation of Akt, regardless of presence of HGF. In addition, PI-103 combined with gefitinib inhibited phosphorylation of both Akt and ERK1/2 in the absence of HGF. The combination of PI-103 and gefitinib inhibited Akt phosphorylation, even in the presence of HGF, but failed to inhibit ERK1/2 phosphorylation. These results confirm our previous observations (7) and further suggest that PI-103 overcomes this resistance by inhibiting phosphorylation of downstream PI3K/Akt. The importance of PI3K/Akt as a target of PI-103 was further supported the evidence obtained in experiments with siRNA for Akt. Treatment with siAkt1 alone knock downed the Akt expression in PC-9 cells (Fig 3B) and resulted in inhibition of cell proliferation by 20% (Fig 3C). Notably, the treatment with siAkt1 reversed HGF-induced gefitinib resistance in combination with gefitinib (Fig 3C).

**PI-103 combined with gefitinib overcomes HGF-induced gefitinib-resistance in vivo.**

We recently established an *in vivo* model by inoculating PC-9 cells pre-mixed with HGF-high producing MRC-5 cells and showed that gefitinib resistance which was abrogated by HGF-MET inhibition (9). Using this model, we next evaluated whether PI-103 overcomes HGF-induced resistance to gefitinib *in vivo*. Consistent with previous observations, we found that treatment with gefitinib alone prevented the enlargement of tumors produced by the mixture of PC-9 cells and MRC-5 cells, but did not cause tumor regression. Since gefitinib induces tumor shrinkage of
PC-9 tumors (9), our results suggest that MRC-5 cells induced gefitinib resistance in vivo. Under these experimental conditions, treatment with PI-103 alone did not inhibit tumor growth, whereas combined treatment with PI-103 and gefitinib dramatically regressed the tumors (Fig 4, A and B). Similar results were reproduced using GDC-0941 which is now used in clinical trials in patients with solid tumors (Supplementary Fig. 4). These combined treatments did not cause obvious side effects, such as weight loss of the mice.

We further examined apoptotic cells in the tumors treated with gefitinib and/or PI-103. While there were few apoptotic cells in control- (Fig 4C) or PI-103-treated tumors (Fig 4D), discernible numbers of apoptotic cells were detected in gefitinib-treated tumors (Fig 4E). However, more apoptotic cells were found in tumors treated with both PI-103 and gefitinib (Fig 4F). (Fig 4 A, B). Immunoblots using these tumors revealed that treatment with PI-103 with or without gefitinib, did not affect the phosphorylation of ERK1/2. On the other hand, PI-103 alone or in combination with gefitinib inhibited Akt phosphorylation in the tumor. Most notably, PI-103 combined with gefitinib induced cleaved caspase 3, the effector caspase that mediate death signaling (Fig 4 G). These results strongly suggested the importance of PI3K/Akt as a target of this combined therapy.

**Short exposure of PI-103 combined with gefitinib further inhibits Akt mediating signal and proliferation of EGFR mutant lung cancer cells**

Our finding, that PI-103 monotherapy did not inhibit tumor growth whereas PI-103 overcame synergistically HGF (MRC-5)-induced gefitinib resistance when combined with gefitinib, was unexpected. Since PI-103 has been reported to have very rapid tissue distribution and tissue clearance in vivo (half life of PI-103 in the major organs is 0.7-1.3h) (12), we hypothesized that rapid tissue clearance of PI-103 might be responsible for its insufficient therapeutic effect in vivo. To mimic pharmacodynamics of PI-103 in vivo, we exposed PC-9 and HCC827 cells to PI-103
transiently for 1h, then washed the cells and incubated the resultant cultures in fresh medium for 48h (Fig 5A). Transient exposure to PI-103 resulted in only ~15% inhibition of the proliferation of PC-9 or HCC827 cells, whereas transient exposure to gefitinib resulted in higher inhibition of proliferation (> 30%). Importantly, transient exposure to both PI-103 and gefitinib inhibited the proliferation of these two cell lines, reaching IC50 (Fig 5B). Analysis using CalcuSyn software (23) indicates that the effect was synergistic. These phenomena were also observed when EGFR mutant cancer cells were co-cultured with MRC-5 cells (Fig 5C) to induce gefitinib resistance, representing the therapeutic efficacy seen in vivo model. By contrast, transient exposure to PI-103 and/or gefitinib did not inhibit proliferation of MRC-5 cells (Fig 5D).

We further evaluated the kinetics of PI3K/Akt phosphorylation after transient exposure of PC-9 cells to PI-103 and gefitinib (Fig 6A). As shown above (Fig 3), 1h treatment with either PI-103 or gefitinib completely inhibited Akt phosphorylation, in the absence of HGF. We found out that, in the absence of HGF, gefitinib, alone or combined with PI-103, inhibited Akt phosphorylation for up to 1h; subsequently, however, Akt phosphorylation in PC-9 cells treated with PI-103 alone started to recover. In the presence of HGF, gefitinib did not inhibit Akt phosphorylation, whereas Akt phosphorylation in PC-9 cells treated with PI-103 alone recovered by 1h after washing. However, cells treated with PI-103 plus gefitinib showed inhibition of Akt phosphorylation 1h after washing (Fig 6A). More importantly, transient exposure to PI-103 plus gefitinib, but not either alone, resulted in induction of cleaved caspase 9 and 3, the initiator and effector caspases that mediate death signaling, and cleaved PARP (Fig 6A). Flow cytometry analyses with Annexin V further confirmed that transient exposure with PI-103 plus gefitinib induced apoptosis of HGF treated PC-9 cells (Fig 6B). These findings indicate that transient exposure to PI-103 combined with gefitinib is sufficient for inducing death signaling even in the presence of HGF, supporting the results observed in vivo experiments.
Discussion

Accumulating evidence indicate that HGF-MET axis is considerable therapeutic target for several solid tumors. HGF can act as autocrine growth factors for glioblastoma, thyroid cancer, and gastric cancer. Moreover, HGF stimulates the invasion and dissemination of various types of cancers (27), as well as inducing EGFR-TKI resistance in EGFR mutant lung cancer. In contrast to MET amplification-induced resistance, restoring the PI3K/Akt pathway and mediated by ErbB3 as adaptor, HGF activates normal MET receptor and induces resistance that restores PI3K/Akt pathway mediated by Gab1/2 as adaptor (7-8). HGF also accelerates expansion of pre-existing clones with MET gene amplification and facilitates induction of EGFR-TKI resistance in a population of EGFR mutant lung cancer (8). In addition, HGF frequently detected in EGFR-TKI resistant tumors with EGFR-T790M second mutation and may induce resistance to irreversible EGFR-TKIs (25). These observations highlight an important role of HGF ligand in controlling of tumor progression and drug sensitivity.

We have shown here that the combination of gefitinib and class I PI3K inhibitors, PI-103 and GDC-0941, overcame HGF-mediated gefitinib-resistance in EGFR mutant lung cancer cells. While HGF restored ERK1/2 and PI3K-Akt phosphorylation via MET activation even in the presence of gefitinib, transient exposure of PI-103 plus gefitinib efficiently inhibited PI3K-Akt phosphorylation, induced death signaling, and caused apoptosis of PC-9 cells. The combined treatment with PI-103 and gefitinib did not inhibit phosphorylation of ERK1/2 (Fig. 3) or STAT3 (data not shown). Recently, it was shown that transient potent inhibition of BCR-ABL kinase activity is associated with maximal clinical benefit in patients with CML (28). Our results illustrate the possibility that transient double blockade of EGFR and PI3K may be useful for controlling HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer.
A large numbers of PI3K inhibitors are developed and are being evaluated in the preclinical and clinical trials (18, 29). PI3K inhibitors have been found to induce G0-G1 cell arrest, rather than apoptosis, and primarily causing stasis of tumor growth in vivo without substantial tumor shrinkage. For example, intraperitoneal administration of high doses of PI-103 (30-70mg/kg) resulted in growth inhibition rather than regression in a range of human tumor xenografts (12, 30). Moreover, in EGFR mutant or k-ras mutant lung cancer models, tumor regression associating with apoptosis was observed only when PI3K-Akt pathway and MEK-MAPK pathway were simultaneously blocked (24, 31). Since these two pathways collaborate with each other to maintain cell survival, simultaneous blockade of both pathways is necessary to induce apoptosis. Surprisingly, our in vitro experiments revealed that, though transient exposure of PI-103 plus gefitinib failed to inhibit ERK1/2 phosphorylation, it caused sustained PI3K-Akt inhibition, induced pro-apoptotic molecules, such as cleaved caspase 3 and 9 and PARP, and thereby induced PC-9 cell-apoptosis even in the presence of HGF. The mechanism by which combined use of PI-103 and gefitinib induces apoptosis of PC-9 cells, even in the presence of HGF, is not fully understood at present. One possible explanation is that double blockade of PI3K-Akt signaling pathway at up-stream (EGFR level) and down-stream (PI3K-Akt level) is efficient for inducing the apoptosis. The other possibility is that combined use of PI-103 and gefitinib inhibited the unknown pathway(s) which are responsible for survival of EGFR mutant lung cancer cells. While the combined therapy did not inhibit phosphorylation of STAT3 (data not shown) in PC-9 cells, we can not rule out the involvement of other unknown pathway(s). Further experiments are warranted to clarify the mechanisms in future.

PI-103 is a class I PI3K inhibitor that reported favorable antitumor activity without any obvious side effects in preclinical animal models (12, 32). Pharmacokinetically, PI-103 is metabolized to form glucuronide and is cleared rapidly from plasma, with metabolism of >70% PI-103 after 30min of incubation with human and mouse microsomes (12). This is consistent
with our results showing that Akt phosphorylation in PC-9 cells treated with PI-103 alone was recovered by 1h (Fig 6). PI-103 is not in clinical trials and work is now in progress to optimize its pharmacokinetics properties by structural modification (13). While continuous exposure for 72h of PI-103 inhibited the proliferation of PC-9 and HCC827 cells, transient exposure for 1h of PI-103 failed to do so in vitro condition. In vivo treatment with PI-103 (5mg/kg i.p., once a day) also failed to inhibit the growth of PC-9 cells mixed with HGF-high producing fibroblasts (MRC-5). Collectively, the insufficient effect of PI-103 monotherapy may be, at least in part, due to short half life and rapid metabolism of this drug in vivo. GDC-0941 (5mg/kg p.o., once a day) also failed to inhibit the growth of PC-9 cells mixed with MRC-5 cells. Though GDC-0941 is a derivative of PI-103 with improved pharmacokinetic and pharmacodynamic properties, intratumoral concentration of GDC-0941 might not be enough to inhibit tumor growth in our in vivo experimental conditions. However, GDC-0941, like PI-103, successfully reversed the resistance when combined with gefitinib (Supplementary Fig 4). Since we did not use maximum tolerated dose of these PI3K inhibitors (70-150mg/kg)(12, 26), our findings suggest that suboptimal dose of PI3K inhibitors may overcome HGF-induced resistance if combined with EGFR-TKIs.

In the present study, we demonstrated the possibility that double blockade of PI3K-Akt signaling pathway at up-stream (EGFR level) and down-stream (PI3K-Akt level) may be useful for overcoming HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells. This concept can be also applicable to circumvent HGF-induced resistance to irreversible EGFR-TKIs (25). Moreover, cancer cell populations were recently shown to exhibit reversible tolerance to EGFR-TKIs by maintaining a phenotypically distinct subpopulation of cells that can protect the overall population from eradication by EGFR-TKIs (33). This reversible tolerance is mediated by activation of IGF-1 receptor (IGF-1R), but can be overcome by IGF-1R inhibitor combined with gefitinib (35). Since PI3K-Akt is involved in IGF-1R-mediating signaling, the
combined use of PI3K inhibitor may also protect against the emergence of reversibly tolerant subpopulations and may potently eradicate EGFR mutant lung cancer. Further investigations in PI3K-Akt signaling pathway are warranted for developing more successful compounds with better activity and safety for EGFR mutant lung cancer patients.
Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgements

We thank Drs. John D. Minna and Yoshitaka Sekido for kindly providing H1975 cells.
References


Legends for Figures

Figure 1. Continuous exposure of PI-103 suppresses the in vitro proliferation of EGFR mutant lung cancer cells, irrespective of the presence of HGF.

Tumor cells were continuously treated with increasing concentrations of EGFR-TKI (gefitinib or erlotinib) or PI-103, with or without HGF, and cell growth was determined after 72 h by MTT assay. Data shown are the representative of five independent experiments. Error bars indicate standard deviation of triplicate cultures. * indicates a P value < 0.001 (Student’s t-test).

Figure 2. PI-103 combined with gefitinib overcomes HGF-induced gefitinib-resistance in vitro. A. Tumor cells were continuously treated with various concentrations of gefitinib and PI-103, with or without HGF, and cell growth was determined after 48 h by MTT assay. B. Tumor cells were co-cultured with human lung fibroblasts (MRC-5) and were continuously treated with indicated concentrations of gefitinib, and/or PI-103. Cell growth was determined after 48 h by MTT assay. Data shown are the representative of three independent experiments. Error bars indicate standard deviation of triplicate cultures.

Figure 3. PI-103 with or without gefitinib suppresses PI3K/Akt pathway even in the presence of HGF. A. Tumor cells were treated with or without gefitinib (1 μmol/L), PI-103 (1 μ mol/L) and/or HGF (20 ng/mL) for 1 h. Then, cells were lysed, and the indicated proteins were detected by immunoblotting. Data shown are the representative of three independent
experiments. **B.** PC-9 cells were treated with three different siRNAs specific for Akt1 or scramble siRNA. **C.** Resultant cells were treated with gefitinib (0.1 μmol/L) and or HGF (20ng/ml) for 48h. Then, MTT assay was performed.

**Figure 4. PI-103 combined with gefitinib overcomes HGF-induced gefitinib-resistance in vivo.** **A.** PC-9 cells (5× 10⁶) mixed with MRC-5 cells (5× 10⁶) were inoculated subcutaneously into SCID mice on day 0. Mice received oral gefitinib (25mg/kg/d) and/or intraperitoneal PI-103 (5mg/kg/d), starting on day 4. The tumor size was measured every 2 d and tumor volumes were calculated as described in Materials and Methods. Data shown are the representative of two independent experiments. Error bars indicate standard errors of 6 mice. * indicates a P value < 0.001 (Student's t-test). **B.** Macroscopic appearances of representative tumors harvested on day 19 are shown. Apoptotic cells were stained by TUNEL method as described in Materials and Methods (C. Control, D. PI-103 alone, E. gefitinib alone, F. gefitinib + PI-103). **G.** Tumors were harvested 1 h after treatment on day 6. Tumor lysates were analyzed by immunoblotting with the indicated antibodies.

**Figure 5. Short exposure of PI-103 combined with gefitinib effectively suppressed the proliferation of PC-9 and HCC827, but not MRC-5 cells.** **A.** Protocol. **B.** Tumor cells were incubated with different concentrations of PI-103 and/or gefitinib for 1h, washed twice with PBS, and incubated in fresh medium for 48h. **C.** Tumor cells were incubated with MRC-5 cells and different concentrations of PI-103 and/or gefitinib for 1h, washed twice with PBS, and co-incubated with MRC-5 cells in fresh medium for 48h. **D.** MRC-5 cells were treated with different concentrations of PI-103 and/or gefitinib for 1h, washed twice with PBS, and further incubated in fresh medium for 48h. The cell growth was determined by MTT assay. Data shown are the
representative of three independent experiments. Error bars indicate standard deviation of triplicate cultures.

**Figure 6. Apoptosis and time kinetics of phosphorylated Akt and pro-apoptotic molecules after short exposure to PI-103 and/or gefitinib.**

**A.** PC-9 cells were incubated (1 \( \mu \)mol/L), PI-103 (1 \( \mu \) mol/L), and/or HGF (20 ng/mL) for 1 h. Then, the resultant cultures were incubated in fresh medium for 1h. Then, the cells were lysed, and the indicated proteins were detected by immunoblotting.

**B.** PC-9 cells were incubated with HGF (20ng/ml) and PI-103 (1 \( \mu \)mol/L), and/or gefitinib (1 \( \mu \)mol/L), for 1h, and then washed two times with PBS. The resultant cultures were incubated in fresh medium for 24 h. The apoptotic cells were determined using Annexin V assay kit, according to manufactory protocol. Values shown are percentage of apoptotic cells.
Figure 1

**PC-9**

- Gefitinib (μmol/L)
- Erlotinib (μmol/L)
- PI-103 (μmol/L)

**HCC827**

- Gefitinib (μmol/L)
- Erlotinib (μmol/L)
- PI-103 (μmol/L)

**HGF (ng/ml)**

- □ 50
- ■ 20
- ○ 10
- ● 0

*Research.*
Figure 2

A

PC-9

HCC827

Growth

%Growth

PI-103 (μmol/L)

HGF (20 ng/ml)

0 0.3 1 0 0.3 1

0 0.3 1 0 0.3 1

B

PC-9

HCC827

Growth

%Growth

Gefitinib (0.1 μmol/L)

PI-103 (1 μmol/L)

MRC-5

- + - + - + - +

- + - + - + - +

- + - + - + - +

- + - + - + - +

- + - + - + - +
Figure 3

(A) Western blot analysis of PC-9 and HCC827 cell lines treated with Gefitinib, PI-103, and HGF. The blots show the expression levels of various proteins including p-MET, MET, p-EGFR, EGFR, p-ErbB3, ErbB3, p-ERK1/2, ERK1/2, p-Akt, Akt, and GAPDH.

(B) Protein levels of Akt and GAPDH in PC-9 cell lines treated with various inhibitors and siAkt1-2.

(C) Growth percentage of PC-9 cell lines treated with Gefitinib and HGF. The results indicate significant inhibition with p<0.001 compared to control.
Figure 4

A

B

C

D

E

F

G

Control PI-103 Gefitinib Gefitinib +PI-103

Tumor Volume (mm³)

0 5 10 15 20 25

Days after inoculation

Control PI-103 Gefitinib Gefitinib +PI-103

C

D

E

F

G

Control Gefitinib PI-103 Gefitinib +PI-103

p-Akt Akt p-ERK1/2 ERK1/2 Cleaved Caspase-3 GAPDH

Research.
Figure 5

**Protocol**

A PC-9 Gefitinib ± PI-103 Fresh medium

1h wash 48h 2h Assay

**Graphs**

B

PC-9

Growth %

- PI-103 (μmol/L) 0 0.3 1

- Gefitinib (1μmol/L)

C

PC-9

Growth %

- PI-103 (μmol/L) 0 0.3 1

- Gefitinib (1μmol/L)

D

MRC-5

Growth %

- PI-103 (μmol/L) 0 0.3 1

- Gefitinib (1μmol/L) 0 1 0 0 1 1
Figure 6

A
PC-9 cells → 1h Gefitinib ± PI-103 → Wash → 1h Fresh medium ± HGF → Harvest

B
PC-9 cells → 1h Gefitinib ± PI-103 → Wash → 48h Fresh medium ± HGF → Annexin V

Gefitinib → − + − − + − + − + +
PI-103 → − − + + − − + + +
HGF → − − − − + + + + +

Annexin V

HGF

GAPDH Cleaved PARP

HGF+PI-103

Cleaved Caspase-9 Cleaved Caspase-3

1.85% 1.28%

2.01% 8.50%

Research.
# Clinical Cancer Research

## Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer

Ivan S Donev, Wei Wang, Tadaaki Yamada, et al.

*Clin Cancer Res* Published OnlineFirst January 10, 2011.

<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-10-1993</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Access the most recent supplemental material at: <a href="http://clincancerres.aacrjournals.org/content/suppl/2011/04/14/1078-0432.CCR-10-1993.DC1">http://clincancerres.aacrjournals.org/content/suppl/2011/04/14/1078-0432.CCR-10-1993.DC1</a></td>
</tr>
<tr>
<td>Author Manuscript</td>
<td>Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.</td>
</tr>
</tbody>
</table>

---

E-mail alerts | Sign up to receive free email-alerts related to this article or journal. |
Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
Permissions | To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org. |